Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $57.10
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have received a consensus rating of “Buy” from the ...
Business Insider29d
Mirum Pharmaceuticals: Strong Financial Performance and Promising Pipeline Support Buy Rating
In a report released today, Michael Ulz from Morgan Stanley maintained a Buy rating on Mirum Pharmaceuticals (MIRM – Research Report), with a price target of $60.00. Discover outperforming ...
Business Insider1mon
Buy Recommendation for Mirum Pharmaceuticals: Strong Financial Performance and Promising Pipeline Drive Optimism
Mirum Pharmaceuticals (MIRM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan Wolleben from JMP Securities reiterated a Buy rating ...
ETF Daily News1mon
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $57.10 Average PT from Analysts
Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million for the quarter, compared to analyst estimates of $81 ...